October 5, 2017 — To provide lifesaving surgical care for sick children in one of the most underserved countries, 13 volunteers including 10 medical personnel from Cincinnati Children’s Hospital Medical Center recently completed their second annual mission to Tanzania. Toshiba Medical, a Canon Group company, donated its Viamo portable ultrasound system during the mission at Bugando Medical Centre in Mwanza, Tanzania, serving about 13 million people in the region.

Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational clinical trial evaluating the impact of fluciclovine (18F) PET/CT imaging on clinical management of men with biochemically recurrent prostate cancer eligible for salvage therapy.

HCA Healthcare Gulf Coast Division and Solis Mammography have entered into a joint venture agreement to make breast health diagnostic services more accessible and convenient across the greater Houston region. The collaboration will result in 16 local sites by the end of 2018, including the Oct. 2 grand opening of a new dedicated breast health center at HCA-affiliated The Woman’s Hospital of Texas.

Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy or internal radiation therapy, for managing locally advanced cervical cancer. Tumor control was significantly better following four fractions of 7 Gray (Gy) each than following two, 9-Gy fractions of high-dose-rate (HDR) brachytherapy, but neither overall survival nor severe treatment-related side effects differed between the treatment groups.

October 4, 2017 — Kubtec announced at the annual conference of the American Association of Pathology Assistants (AAPA) that they are expanding their proprietary use of 3-D tomosynthesis by bringing it to the XPERT 80 Specimen X-ray System. Kubtec introduced 3-D imaging for clinical specimens with the Mozart System, the first specimen X-ray system to use 3-D tomosynthesis, according to the company. 
 

In the 1980s I was enthralled with hybridomas. Created by fusing human tumor cells with cells from mouse spleens that had been sensitized to the patient’s own cancer, they were supposed to pump out the magic bullets that finally would take cancer down. At the time, I believed it.

Thirty years later, the jury is still out.

Immune technology is taking some impressive steps. But it has not lived up to early expectations.


According to a new Market Study Report,1 the automated breast ultrasound system (ABUS) market will see a 21 percent compound annual growth rate (CAGR) from 2017-2024, driven by rising incidence of breast cancer and volume scanner segment dominating this growth.



Over the years, significant progress has been made educating women, men and families about breast cancer — the pink ribbon has become the universal symbol of breast health and awareness, and more women than ever before know about the disease, the risks it poses and the necessary steps to take to prevent and detect it early.



In an era of population health consciousness and uncertainty regarding regulations, healthcare facilities need to be able to rely on technology as a constant in a sea of change. As healthcare facilities move to value-based care, they need to be able to rely on their healthcare technology partner. This extends beyond the initial equipment investment to continued service and support. The service and support a partner provides after the sale can be more important than the sale itself.



The healthcare analytics market is witnessing a phenomenon of sorts, with an increasing number of remote consultations and monitoring practices across the globe. The surging adoption of smartphones and tablets will favorably attribute the product demand across a myriad of medical application arenas such as financial, clinical and operations management. 


Subscribe Now